Why the study?
A standardized method for evaluating and monitoring cardiotoxicity does not exist, leaving patients dependent on nonspecific and lengthy tests and often diagnosed only after irreversible heart damage.
Can a panel of circulating biomarkers be used to monitor time-dependent changes in doxorubicin-induced cardiotoxicity in Wistar rats?
Can a panel of circulating biomarkers be used to monitor time-dependent changes in doxorubicin-induced cardiotoxicity in Wistar rats?
A panel of circulating biomarkers was assessed in a rat model to potentially enhance the accuracy of screening for doxorubicin-induced cardiotoxicity.
Biomarker panel detects doxorubicin cardiotoxicity in rats; hypothesis-generating and should not change clinical monitoring yet.
The number of cancer survivors is increasing as cancer therapies become more and more effective. As a consequence, cardio-oncology is nowadays more shifted towards detecting and treating conditions such as CTOX, which refers to heart damage as a result of cancer treatment. Currently, a standardized way of evaluating and monitoring CTOX does not exist, and patients undergo nonspecific and lengthy tests, so they are often diagnosed when heart damage is irreversible. Thus, we assessed a panel of circulating biomarkers that can be used to monitor time-dependent changes in Wistar rats treated with conventional or liposomal DOX. After validation this panel might be applied in clinics to enhance accuracy of screening patients undergoing DOX-based therapy approaches.
No takes yet. Share an insight, caveat, or question.
Anca et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: